Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

SIR 2023 Conference Coverage

N. Kothary

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

Opus One: Final Results - RFA in Axial Skeleton

Jason Levy

Hypercalcaemia & Hypocalcaemia

Obafemi Awolowo University

D. Soyoye

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Cleveland Clinic Taussig Cancer Institute

A. Mehdi

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favo…

2024 ASCO® Annual Meeting Insights Hub

M. Zarba

EASD Insights: Long-term Complications in Diabetes - From Classical …

Stephan Herzig

Overview of a SoC in 1L mRCC Focusing on the Long-Term Survival Data

David McDermott

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

RCC Highlights From ASCO® GU 2024

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

ASCO® 2024 Insights: "Belzutifan for Advanced Renal Cell Carcinoma"

2024 ASCO® Annual Meeting Insights Hub

E. Jonasch

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation …

2024 ESMO Annual Meeting Insights Hub

C. Ciccarese